Squarepoint
KLRS

Squarepoint’s Kalaris Therapeutics KLRS Stock Holding History

Squarepoint’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$229K Buy
39,773
+14,406
+57% +$128K ﹤0.01% 3886
2025
Q4 		$214K Sell
25,367
-14,806
-37% -$94.7K ﹤0.01% 3822
2025
Q3 		$232K Sell
40,173
-18,922
-32% -$62.5K ﹤0.01% 3846
2025
Q2 		$158K Buy
59,095
+44,508
+305% +$201K ﹤0.01% 4050
2025
Q1 		$117K Sell
14,587
-106
-0.7% -$1.04K ﹤0.01% 4181
2024
Q4 		$142K Buy
+14,693
New +$222K ﹤0.01% 4589
2024
Q1 		– Sell
-12,397
Closed -$194K – 4722
2023
Q4 		$194K Buy
12,397
+9,682
+357% +$382K ﹤0.01% 3607
2023
Q3 		$134K Sell
2,715
-1,437
-35% -$97.9K ﹤0.01% 3513
2023
Q2 		$325K Buy
4,152
+954
+30% +$90.7K ﹤0.01% 2918
2023
Q1 		$290K Buy
3,198
+38
+1% +$4.84K ﹤0.01% 2593
2022
Q4 		$373K Buy
+3,160
New +$536K ﹤0.01% 2458
2022
Q3 		– Sell
-738
Closed -$66K – 3541
2022
Q2 		$66K Sell
738
-489
-40% -$51.3K ﹤0.01% 2681
2022
Q1 		$190K Buy
1,227
+562
+85% +$112K ﹤0.01% 2492
2021
Q4 		$198K Buy
+665
New +$308K ﹤0.01% 2708
2021
Q3 		– Sell
-950
Closed -$431K – 3535
2021
Q2 		$431K Buy
+950
New +$491K ﹤0.01% 2253

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Squarepoint's KLRS Position: Q1 2026 in Review

Squarepoint increased its Kalaris Therapeutics (KLRS) stake by 57% in Q1 2026, buying an estimated $128K and bringing the position to 39,773 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #3886.

Squarepoint first reported a position in KLRS in Q2 2021 and has held it in 15 quarters since. The position peaked at $431K in Q2 2021. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Squarepoint held 39,773 shares of Kalaris Therapeutics worth $229K as of Q1 2026.
  • Squarepoint bought 14,406 Kalaris Therapeutics shares in Q1 2026, an estimated $128K.
  • Kalaris Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3886 holding.
  • Squarepoint first reported a position in Kalaris Therapeutics in Q2 2021 and has held it in 15 quarters since.
  • Squarepoint's Kalaris Therapeutics position peaked at $431K in Q2 2021.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.